Quadrant Capital Group LLC Sage Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $2.65 Billion
- Q1 2025
A detailed history of Quadrant Capital Group LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 4,859 shares of SAGE stock, worth $31,729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,859
Previous 2,019
140.66%
Holding current value
$31,729
Previous $10,000
280.0%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding SAGE
# of Institutions
217Shares Held
49.9MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$34.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$33.2 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$29.2 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$17.8 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$13.6 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $388M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...